Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Mini Oral session: GI, lower digestive

LBA28 - Prognostic effect of imaging and CEA follow-up in resected colorectal cancer (CRC): Final results and relapse free survival (RFS) - PRODIGE 13 a FFCD phase III trial


12 Sep 2022


Mini Oral session: GI, lower digestive


Tumour Site

Colon and Rectal Cancer


Come Lepage


Annals of Oncology (2022) 33 (suppl_7): S808-S869. 10.1016/annonc/annonc1089


C. Lepage1, J.M. Phelip2, L. Cany3, E. Barbier4, S. Manfredi5, P. Deguiral6, R. Faroux7, M. baconnier8, D. Pezet9, E. terrebonne10, A. Adenis11, M. Ben Abdelghani12, J.F. AIN13, G. Breysacher14, I. Boillot Benedetto15, A. Pelaquier16, A. Lievre5, P. Laurent puig17, F. Bibeau18, O. Bouche19

Author affiliations

  • 1 Hepato Gastroenterology And Digestive Oncology Dept., CHU Dijon, 21079 - Dijon/FR
  • 2 Digestive Oncology, CHU Saint Etienne - Hopital Nord, 42055 - Saint-Étienne/FR
  • 3 Oncology Department, Clinique Francheville, 24000 - Périgueux/FR
  • 4 Biostatistics, Fédération Francophone de Cancérologie Digestive, 21000 - Dijon/FR
  • 5 Digestive Oncology, CHU de Rennes - Hopital Pontchaillou, 35033 - Rennes, Cedex /FR
  • 6 Oncology Department, Clinique Mutualiste de l'Estuaire, 44606 - Saint-Nazaire/FR
  • 7 Digestive Oncology, CHD Vendee - Hopital Les Oudairies, 85925 - La Roche-sur-Yon/FR
  • 8 Digestive Oncology, CH Annecy Genevois, 74011 - Annecy/FR
  • 9 Surgery, CHU Estaing, 63003 - Clermont-Ferrand/FR
  • 10 Digestive Oncology, CHU Bordeaux - Hopital St. André, 33000 - Bordeaux/FR
  • 11 Medical Oncology Department, ICM - Institut du Cancer de Montpellier, 34298 - Montpellier, Cedex /FR
  • 12 Oncologycology Department, ICANS - Institut de Cancérologie Strasbourg Europe, 67200 - Strasbourg/FR
  • 13 Surgery, polyclinique val de saone, 71000 - Macon/FR
  • 14 68, Hopital Louis Pasteur, 68024 - Colmar/FR
  • 15 Surgery, Saint joseph-Saint Luc, Lyon/FR
  • 16 Digestive Oncology, Centre Hospitalier Montelimar Service de Oncologie, 26200 - Montelimar/FR
  • 17 Digestive Oncology, Paris Descartes University, 75006 - Paris/FR
  • 18 Service D'anatomie Pathologique, CHU de Caen - Hopital Cote de Nacre, 14033 - Caen/FR
  • 19 Digestive Oncology, CHU de Reims - Hôpital Robert Debré, 51092 - Reims, Cedex/FR


Login to access the resources on OncologyPRO.

Abstract LBA28


Intensive follow-up of patients (pts) after curative surgery for CRC is recommended by various scientific societies. However, the few clinical trials performed are controversial and no survival benefit has been demonstrated to date.


PRODIGE 13 is a cooperative prospective multicentre controlled phase III trial evaluating by double randomisation the impact of i) intensive radiological monitoring (CT-scan/6m) vs. a standard one (abdominal ultrasound/3m and thoracic radiography/6m) and ii) CEA assessment vs. no, in the follow-up of stage II or III CRC resected for cure. The primary endpoint was 5-year overall survival (OS). The result of the 2d intermediate analysis: after curative surgery for primary CRC, the addition of CEA and/or CT does not provide any benefit in 5-year OS for the global population of the study. We report here the final results of the RFS.


At all, 75.9% of the pts were < 75 years old (16% rectal, 44% left colon cancers (CC)). Among CC 52% were Stage II (25% adjuvant chemotherapy). With a median follow-up of 7,8 years, cancer recurrence was detected in 22,3% of the pts (39%/61% stage II/III). The recurrence was metastatic in 89.5% and local in 10.5% of the pts. Overall, 5.9% of the pts (95% CI,4.6%-7.2%) were treated for recurrence with curative intent (A: intensive imaging + CEA 37.6%; C: Standard imaging + CEA 50.5%; B: intensive imaging alone 35.1%; D: Standard imaging alone 30.2%; p= 0.0120). The 5-years RFS rates were respectively 71.8%, 74.6%, 69.0% and 67.5% in arm A, B, C and D. Compared with minimum follow-up (D), pts of the arm D had significantly longer RFS, 0,80 ([0.65;0.98]; p= 0.031). The 5-years RFS were respectively 73.2% [70.3;75.8] and 68.2% [65.2;71.0] in CTscan surveillance group vs. not (HR 0.86 [0.75;1]; p=0.052) and 70.4% [67.42; 73.1] and 71.0% [68.1; 73.75] in CEA surveillance vs. not respectively (HR 0.99 [0.86;1.15]; ns).


Among pts who had undergone curative surgery for primary CRC, intensive imaging, but not CEA screening, provided an increased rate of surgical treatment of recurrence with curative intent. There is no survival advantage to any strategy but a trend toward a better 5-years RFS in the CT scan surveillance group versus not.

Clinical trial identification


Editorial acknowledgement

Legal entity responsible for the study

FFCD: Federation Francophone de Cancérologie Digestive.


FFCD: Federation Francophone de Cancérologie Digestive.


C. Lepage: Financial Interests, Personal, Invited Speaker: Ipsen, Amgen, Pierre Fabre; Financial Interests, Personal, Advisory Board: Novartis. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.